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Not of NOD2/CARD15 Is Associated with
Graft-versus-Host Disease after Hematopoietic
Stem Cell Transplantation in Children
Bernd Gruhn,1 Juliane Intek,1 Nadine Pfaffendorf,1 Roland Zell,2 Selim Corbacioglu,3
Felix Zintl,1 James F. Beck,1 Klaus-Michael Debatin,3 Daniel Steinbach3Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after hematopoietic stem cell
transplantation (HSCT). The selectionof a suitable donor is themost critical issue in preventing severeGVHD.
Recent data suggest that the risk of GVHDdoes not only depend on human leukocyte antigens (HLA) but also
on polymorphisms of genes that influence immune responses. We analyzed the 1142 G.A single-nucleotide
polymorphism (SNP) in the interleukin-23 receptor gene (IL23R) and 3 SNPs in the NOD2/CARD15 gene in
a cohort of 231 children who underwent allogeneic stem cell transplantation and/or their respective donors.
Noassociationwasobserved between anyof theNOD2/CARD15polymorphisms andGVHD in eitherdonor
or recipient. Likewise, the IL23R polymorphism in the recipient was not significantly associated with GVHD.
We found a significantly reduced incidence of acute GVHD (aGVHD) grade II-IV in patients who were trans-
planted from a donor with the IL23R polymorphism (5.0% versus 33.3%; P5.009). There was no case of
aGVHD grade III-IV if this polymorphism occurred in the donor. These findings could be particularly relevant
for children with inborn metabolic or immunologic disorders who do not benefit from a graft-versus-tumor
effect, and therefore, selection of a donor with the IL23R polymorphism might be beneficial.
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NOD2/CARD15INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is
a therapeutic option for many patients with progressive
malignant hematologic malignancies as well as for pa-
tients with a number of inherited metabolic and immu-
nologic disorders. One of the main complications of
HSCT is the development of graft-versus-host disease
(GVHD) caused by immune competent T cells in the
graft. If this immunereaction isdirectedagainst leukemic
cells, it is called a graft-versus-leukemia (GVL) effect,
and can contribute to the therapeutic effect of HSCT.1Department of Pediatrics, University of Jena, Jena, Ger-
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6/j.bbmt.2009.08.001The risk of GVHD is influenced by the constella-
tion of major and minor histocompatibility antigens
(HLA) between the patient and the donor. However,
recent data suggest that the risk of GVHD also
depends on polymorphisms of genes that influence
immune responses [1]. Examples of such genes are
NOD2/CARD15 and the interleukin-23 receptor
(IL23R) gene. The NOD2/CARD15 gene encodes
a protein that functions as a sensor for muramyl dipep-
tide, which is a cell wall component in bacteria. Among
other functions it takes part in the regulation of
inflammatory response through intracellular path-
ways involving nuclear factor kB and IkB kinase [2].
IL23R is expressed in T cells and upon stimulation in-
duces proliferation and interferon (IFN)-g production
[3,4].
A number of studies analyzed the association be-
tween NOD2/CARD15 polymorphisms and outcome
of HSCT [5-13]. It was initially found that the pres-
ence of at least 1 of 3 polymorphisms of the gene in
either donor or recipient was associated with a higher
incidence of acute GVHD (aGVHD) and treatment-
related mortality (TRM). The higher TRM was not
only because of aGVHD, but also because of acute1571
Table 1. Characteristics of Patients and Donors
Number
231
Percent
100.0
Patient characteristics
Sex male 149 64.5
female 82 35.5
Median age (range) 11 (0-29)
GVHD Prophylaxis MTX + CsA 148 64.1
CsA 46 19.9
MTX 16 6.9
no prophylaxis 21 9.1
Underlying disease AML 53 22.9
ALL/NHL 100 43.3
MDS 26 11.3
CML 18 7.8
SAA 14 6.1
malignant histiocytosis 1 0.4
Wiscott-Aldrich Syndrome 1 0.4
severe combined
immunodeficiency
2 0.9
infantile septic
granoulomatosis
2 0.9
osteopetrosis 3 1.3
storage diseases 8 3.5
congenital
amegacaryocytosis
1 0.4
Blackfan-Diamond-Anemia 2 0.9
Donor characteristics
1572 Biol Blood Marrow Transplant 15:1571-1577, 2009B. Gruhn et al.or chronic respiratory failure [5]. Following studies
showed that the impact on TRM is particularly pro-
nounced in T cell-depleted transplantation [9], and
that it is more prominent in HLA-identical sibling
transplantation compared to unrelated donor trans-
plantation [6]. A very strong association exists between
the recipient NOD2/CARD15 variants and the devel-
opment of bronchiolitis obliterans after HSCT [8].
The only available study on IL23R found a strong
correlation between the polymorphism 1142 G.A in
the donor and a decreased risk of aGVHD [14].
The main clinical potential of these observations is
to include the NOD2/CARD15 and IL23R polymor-
phisms in the donor selection process. All of the above
studies analyzed adult patients. Therefore, it is not
clear whether the same consequences apply to pediat-
ric patients. Children differ from adult patients in
terms of underlying disease, pretreatment, comorbid-
ity, vulnerability of organs, and the maturation stage
of their immune system.
We present here the first study on the relevance of
NOD2/CARD15 or IL23R polymorphisms for
GVHD in pediatric patients.Sex male 137 59.3
female 94 40.7
Tissue compatibility MFD 101 43.7
MUD 91 39.4
MMD 25 10.8
haploidentical 14 6.1
Cell type bone marrow 167 72.3
peripheral stem cells 64 27.7
MTX indicates methotrexate; CsA, cyclosporine A; AML, acute myelog-
enous leukemia; ALL, acute lymphoblastic leukemia; NHL, Non-Hodgkin
lymphoma; MDS, myelodysplastic syndrome; CML, chronic myeloge-
nous leukemia; SAA, severe aplastic anemia; MFD, matched family do-
nor; MUD, matched unrelated donor; MMD, mismatched donor;
GVHD, graft-versus-host disease.PATIENTS AND METHODS
Patients
The study population consisted of 231 children or
adolescents and their respective donors who under-
went stem cell transplantation at the University
Children’s Hospital Jena between 1982 and 2007.
The criteria for enrolment in this study were avail-
ability of cryopreserved pretransplantation blood or
bone marrow (BM) cells and the informed consent
from the patients and/or their parents. The clinical
characteristics of the patients are described in Table 1.
Allogeneic BM (n5167) or peripheral blood stem
cells (PBSCs; n564) were used for transplantation.
The donor was HLA-matched unrelated in 39%
(n591) of transplants and HLA-identical related in
44% (n5101) of transplants. Fourteen (6%) patients
where transplanted from haploidentical related do-
nors and 25 (11%) patients from HLA-mismatched
donors.
Conditioning regimen was myeloablative (MA) in
all cases. Two forms of GVHD prophylaxis predomi-
nated: cyclosporine A (CsA) and methotrexate (MTX)
in 148 (64%) transplants and cyclosporine A (CsA)
alone in 46 (20%) transplants.MTXalonewas adminis-
tered in 17 (7%) transplants. In 20 (9%) transplants, no
GVHD prophylaxis was given. These were high-risk
patients with leukemia in whom a strong GVL effect
was considered indispensable for successful treatment.
aGVHD and chronic GVHD (cGVHD) was
diagnosed and graded according to standard criteria
[15,16].SingleNucleotide Polymorphism (SNP)Analysis
Samples were obtained from blood or BM aspirates.
Mononuclear cells were purified by Ficoll-Hypaque
(Sigma, St. Louis, MO) density gradients (density
.1.077 g/mL) and cryopreserved in liquid nitrogen.
Genomic DNA was isolated using the High Pure PCR
Template Preparation Kit (Roche, Mannheim, Ger-
many) according to manufacturer’s instructions. The
genotype was determined using ready to use TaqMan
SNP Genotyping Assays and the ABI PrismTM 7700
Sequence Detector (Applied Biosystems, Foster City,
CA) according tomanufacturers instructions.TheAssay
IDs were: IL-23R-1142 G.A (SNP ID: rs11209026):
C_1272298_10; NOD2/CARD15 SNP8 (SNP ID:
rs2066844): C_11717468_20; and NOD2/CARD15
SNP12 (SNP ID: rs2066845): C_11717466_20. Details
about these assays are available at www.appliedbiosys-
tems.com.
No ready-to-use assay was available for NOD2/
CARD15 SNP13 (SNP ID: rs2066847). Therefore,
Biol Blood Marrow Transplant 15:1571-1577, 2009 1573GVHD and Polymorphism of IL23 Receptora Custom TaqMan SNP Genotyping Assay was
provided by Applied Biosystems:
Probe1: 200 nM; FAM-labeled; CTGCAGGCCC
TTGA MGB;
Probe2: 200 nM; VIC-labeled; CTGCAGGCCCC
TTGA MGB;
Primer F: 900 nM; GTCCAATAACTGCATCAC
CTACCT;
Primer R: 900 nM; ACTTCCAGGATGGTGTC
ATTCC
In 4 randomly selected samples, the genotype of
IL23R was also analyzed by direct sequencing. In
each sample, the TaqMan result was verified.
We used primer IL23R 1 and IL23R 2 with the
following sequences:
IL23R1: 500 nM; AATGAAGACTAATGCTTGG
IL23R2: 500 nM; TGTAGAGAGTTTGGCA
TGG
Polymerase chain reaction (PCR) was performed
using 500 ng DNA and 1.25 units of Taq DNA poly-
merase (Roche), in a 50-mL reaction, which contained
10 mmol/L Tris-HCl (pH 8.8), 200 mmol/L each
dATP, dGTP, dCTP, dTTP, and 0.5 mmol/L each
primer. Samples were subjected to an initial 5 min
denaturation at 94C, followed by 40 cycles of 1-min
denaturation at 94C, 1-min annealing at 55C, and
1-min extension at 72C in a Peltier Thermal Cycler,
model PTC-200 (MG Research, Watertown, MA). A
final 10-min extension was performed at the end of
the PCR amplification. Aliquots of the PCR (10 mL)
were analyzed on a 3% Nusieve GTG agarose gel
(FMC, Rockland, ME) with ethidium bromide (0.05
mg/mL) staining. To purify the PCR product for
sequencing, amplified DNA was run on a 2% Nusieve
agarose gel (FMC) and the ethidium bromide-stained
band was located and excised. Agarose was removed
using QIAquick Gel Extraction Kit (Qiagen, Chats-
worth, CA) according to the manufacturer’s instruc-
tions. The same PCR primers were also used for
sequencing of the amplicons. Sequencing reactions
using DyeNamic ET Terminators were performed
according to the cycle sequencing protocol (Pharmacia
Life Sciences, Freiburg, Germany). The products were
ethanol precipitated and analyzed on a Prism 310
Genetic Analyzer of ABI. The sequences were aligned
manually.RESULTS
Frequency of Polymorphisms
Two hundred thirty-one donor/patient pairs were
analyzed. Cell samples from the patient were availablein 217 cases. Samples from the donor were available in
181 cases. Cells from donor and patient were available
in 168 pairs. The frequency of the polymorphisms in
patients and donors were similar to previously pub-
lished data [5-14].
The IL-23R-1142 G.A allele was found in 17
(7.8%) patients and 20 (11%) donors. None of the
individuals was homozygous for this SNP. In 5
cases, the polymorphism was found in donor and
patient.
The frequencies of theNOD2/CARD15 polymor-
phisms were: SNP8: 16 (7.4%) patients and 16 (8.8%)
donors, 1 patient was homozygous; SNP12: 5 (2.3%)
patients and 8 (4.4%) donors, none homozygous;
SNP13: 21 (9.6%) patients and 12 (6.6%) donors, 2
patients were homozygous.
At least 1 of the NOD2/CARD15 polymorphisms
was found in 41 (18.9%) patients and 33 (19.6%)
donors. In 12 cases, at least 1 polymorphism was found
in the donor and in the patient.Frequency of GVHD
aGVHD was observed in 107 patients (26%). The
involved organs were skin (n582), gut (n550), and
liver (n533). cGVHD was observed in 51 patients
(22%). The most frequently involved organs were
skin (n533), oral mucosa (n523), liver (n521), sicca
syndrome (n515), lung (n59), and gut (n510).IL-23R Polymorphism and aGVHD
Significantly lower levels of aGVHD were associ-
ated with the presence of the IL23R-1142 G.A allele
in the donor (Spearman correlation P5.024; Figure 1).
Only 1 of 20 patients (5%) who were transplanted from
a donor with this polymorphism developed aGVHD
higher than grade I (Table 2), whereas 53 of 161 pa-
tients (33.3%) who had a donor without this SNP
developed aGVHDhigher than grade I (Fisher’s Exact
Test, P5.009).
The association between aGVHD and the IL23R-
1142 G.A allele in the donor was not restricted to
a specific tissue but equally pronounced for skin, gut,
and liver.
To test whether this correlation was because of
other differences between those patient groups, we
compared the main patient and donor characteristics
of transplants with an IL-23R-1142 G.A-positive do-
nor and transplants from a donor without this poly-
morphism. As shown in Table 3, no significant
differences were observed.
The frequency or severity of aGVHD was not as-
sociated with the occurrence of the IL23R-1142
G.A allele in the patient. The frequency of aGVHD
grade II-IV was 18% (3 of 17) if the polymorphism
was present versus 29% (58 of 200) if it was not.
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Figure 1. The IL23R-1142 G.A allele in the donor is associated with
less severe and less frequent GVHD (Spearman correlation P5.024).
Donor IL23R-1142 G.A positive, n520; donor IL23R-1142 G.A neg-
ative, n5161.
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G.A allele was present in both individuals and no
aGVHD was observed.NOD2/CARD15 Polymorphisms and aGVHD
The association of each of the 3 NOD2/CARD15
polymorphisms with aGVHD was analyzed in 2 ways.
First, the Spearman correlation coefficient was calcu-
lated, and second, the Fisher’s Exact Test was calcu-
lated for aGVHD grade 0 or I versus aGVHD grade
II to IV (Table 2).
We did not observe a trend for an association of
any of the 3 polymorphisms with the occurrence of
aGVHD (Table 2).Table 2. Acute GVHD and Polymorphisms of IL23R and
NOD2/CARD15
GVHD grade II-IV Fishers
Exact Test
P-Valueyes no
Donor
genotype
IL23R 1142 G>A yes 1 19 .009
no (wt) 53 108
NOD2/CARD15
SNP8
yes 5 11 1.0
no (wt) 49 116
NOD2/CARD15
SNP12
yes 3 5 .7
no (wt) 51 122
NOD2/CARD15
SNP13
yes 3 9 1.0
no (wt) 51 118
Any NOD2/
CARD15 SNP
yes 10 23 1.0
no (wt) 44 104
Receptor
genotype
IL23R 1142 G>A yes 3 14 .24
no (wt) 58 142
NOD2/CARD15
SNP8
yes 3 13 .56
no (wt) 58 143
NOD2/CARD15
SNP12
yes 1 4 1.0
no (wt) 60 152
NOD2/CARD15
SNP13
yes 7 14 .71
no (wt) 54 142
Any NOD2/CARD15
SNP
yes 11 30 1.0
no (wt) 50 126
GVHD indicates graft-versus-host disease; SNP, single nucleotide poly-
morphism.The result was the same in a combined analysis of
the 3 polymorphisms. At least 1 of the 3 polymor-
phisms was observed in 41 (18.9%) patients and 33
(19.6%) donors, but neither group differed signifi-
cantly in terms of frequency or severity of aGVHD.
Polymorphisms of NOD2/CARD15 or IL23R and
cGVHD
Wefirst analyzed the association of the 4 polymor-
phisms with overall cGVHD, independent of the in-
volved organs. The genotypes of donors and patients
were analyzed separately. Neither the IL23R polymor-
phism nor any of the 3 NOD2/CARD15 polymor-
phisms were significantly associated with the
frequency of cGVHD. The result was the same in
a combined analysis of the 3 NOD2/CARD15 poly-
morphisms, that is, all donors who had at least 1 of
the polymorphisms and all patients, respectively.
Because the rate of cGVHD in peripheral cells
versus marrow as a donor source is higher, these
analyses were repeated with the type of transplant
as a stratification variable. The results remained
insignificant.
In a second step we performed the same analyses
but separately for each of the most frequently
involved organs (skin, oral mucosa, liver, saliva
glands, lung, and gut). No significant associations
were observed, but the subgroups are too small for
reliable conclusions.
Polymorphisms of NOD2/CARD15 or IL23R and
Survival
The influence of the IL23R polymorphism and
each of the 3 NOD2/CARD15 polymorphisms on
overall survival (OS) was analyzed by Kaplan-Maier
statistics. No significant association between survival
and any of the polymorphism in either donor or
patient was found (Figure 2).
Results in Children up to 16 Years
Our main goal was to analyze the relevance of
NOD2/CARD15 and IL23 in pediatric patients.
Initially, we included all patients who were trans-
planted in our children’s hospital. However, some of
the patients were young adults, the oldest being 29
years at the time of transplantation. Therefore, all
analyzes were repeated with a restriction to patients
aged 16 years or younger (n5199).
The correlation between the presence of the
IL23R-1142 G.A allele in the donor and lower levels
of aGVHD was also significant in this subgroup
(Spearman correlation coefficient P5.024). In patients
with aGVHD grade 0 or I, this polymorphism was
found in 32% (43/135) of the donors. In patients
with aGVHD grade II to IV it was found in 0% (0/
17) of the donors (Fisher’s Exact Test, P5.003).
Table 3. Comparison of Transplants with IL23R-1142 G>A in the Donor Versus Wild-Type of IL23R in the Donor
IL23R-1142 G>A in the Donor
P-Value
Yes No (wt)
Number Percent Number Percent
20 100 161 100
Patient characteristics
Sex male 12 60 102 63 .89
female 8 40 59 37
Median age (range) 12 (3-19) 10 (0-26) .1
GVHD Prophylaxis MTX + CsA 11 55 104 65 .32
CsA 8 40 38 24
no prophylaxis 1 5 19 12
Underlying disease AML 3 15 37 23 .8
ALL/NHL 11 55 68 42
MDS 4 20 22 14
CML 1 5 11 7
SAA 0 0 10 6
other 1 5 13 8
Donor characteristics
Sex male 11 55 98 61 .64
female 9 45 63 39
Tissue compatibility MFD 5 25 56 35 .86
MUD 11 55 74 46
MMD 3 15 20 12
haploidentical 1 5 11 7
Cell type bone marrow 13 65 105 65 1.0
peripheral stem cells 7 35 56 35
MTX indicates methotrexate; CsA, cyclosporine A; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; NHL, Non-Hodgkin lym-
phoma; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; SAA, severe aplastic anemia; MFD, matched family donor; MUD, matched
unrelated donor; MMD, mismatched donor; GVHD, graft-versus-host disease.
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total group of patients remained insignificant in this
subgroup.DISCUSSION
We here report the first data on the clinical
relevance of NOD2/CARD15 and IL23R polymor-
phisms for GVHD in children. Our results show that
the polymorphism IL23R-1142 G.A in the donor is
associated with a significantly lower frequency and
severity of aGVHD in the patient (Figure 1). This is
consistent with the only available study on IL23R-
1142 G.A and aGVHD in adult patients [14].
The main limitation of our analysis is the strong
heterogeneity of the study population (Table 1). How-
ever, the main characteristics of patients and donors
did not significantly differ between transplants with
wild-type versus IL23R-1142 G.A-positive donors
(Table 3). Therefore, it is unlikely that this is a false
positive finding.
The IL-23R polymorphism was not associated
with superior OS. The reason could be that patients
with less GVHD also experience less GVL effect,
and hence, have a higher risk of relapse. In our cohort
of leukemia patients the number of relapses was not
higher after transplantation from a donor with the
IL-23R polymorphism. A detailed analysis of thishypothesis will require prospective studies with larger
numbers of patients and less heterogeneity of diseases.
Patients with inborn metabolic or immunologic
disorders represent a growing proportion of pediatric
stem cell transplantations. These patients do not
need a GVL effect. Therefore, they would probably
benefit from a donor with the IL23R polymorphism.
A number of studies have analyzed the relevance of
NOD2/CARD15 polymorphisms for GVHD in adult
patients [5-13]. Initial reports suggested that the pres-
ence of any of the 3 polymorphisms (SNP8, SNP12,
and SNP13) in donor or patient was associated with
more severe aGVHD and TRM [5]. Most of the fol-
lowing studies confirmed the higher incidence of
TRM but produced controversial results concerning
the risk of aGVHD [6-12]. Sairafi et al. [13] observed
neither an association with aGVHD nor with TRM
in a large single center study. Hildebrandt et al. [8]
demonstrated a strong association between the recipi-
ent NOD2/CARD15 variants and the development of
bronchiolitis obliterans after HSCT in adult patients.
In our pediatric patient group, we found no corre-
lation of the NOD2/CARD15 polymorphisms in ei-
ther donor or patient with aGVHD, cGVHD, or OS.
The result was the samewhen onlyTRMwas analyzed.
It is possible that we failed to observe such an associa-
tion because of the heterogeneity in the patient popula-
tion. However, because we did not even see a trend for
more severe aGVHD, cGVHDor a highermortality in
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Figure 2. Polymorphisms of IL23R and NOD2/CARD15 are not associated with OS after stem cell transplantation in children. (A) Patient IL23R-1142
G.A positive (n517) versus patient IL23R-1142 G.A negative (n5200). (B) Donor IL23R-1142 G.A positive (n520) versus donor IL23R-1142 G.A
negative (n5161). (C) Patient positive for any of the 3 SNPs in NOD2/CARD15 (n541) versus patient negative for all 3 SNPs (n5176). (D) Donor
positive for any of the 3 SNPs in NOD2/CARD15 (n533) versus patient negative for all 3 SNPs (n5148).
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likely that the genotype ofNOD2/CARD15 is ofmajor
relevance for the outcome of HSCT in children.ACKNOWLEDGMENTS
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